Pfizer secures rights for RSV therapeutic candidate sisunatovir in China
Pharmaceutical Technology
DECEMBER 20, 2022
The deal is pursuant to the existing strategic collaboration of the companies for expanding patient access to new therapeutics in Greater China. Now, Pfizer will lead all the development, commercialisation activities as well as costs for the RSV therapeutic candidate in the regions.
Let's personalize your content